Harshabad Singh, MB, BS
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Harshabad Singh, MB, BS
Dana-Farber Cancer Institute
EDUCATIONAL TITLES
HCC PROGRAM AFFILIATION
Publications from Harvard Catalyst Profiles
- Lee JK, Quintanilha JCF, Chen KT, Fendler B, Tambaoan CFB, Graf R, Odzer N, Pusztai L, Lustberg M, Singh H, Strickland M, O'Meara TA, Tolaney SM, Yap TA, Ross J, Gasco Hernandez A, Decker B, Huang RSP, Klempner SJ, Sokol ES, Schrock AB. The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets. Clin Cancer Res 2026. PubMed
- Char SK, Singh H, Ng K. Biomarkers for Early Detection and Monitoring of Colorectal Cancer. Gastroenterol Clin North Am 2026; 55:143-164. PubMed
- Gaglione SA, Mukkamala RS, Krishna C, Smith BE, Wadsworth MH, Jelinsky SA, Perez CR, Schmidt-Hong L, Katz EL, Gellatly KJ, Ali LR, Shen J, Holec PV, Zhao QH, Chan AO, Xu EJK, Kravarik KM, Guzova JA, Dobson CS, Singh H, Garber M, Dougan M, Dougan SK, Harris JE, Winkler A, Birnbaum ME. Scalable TCR synthesis and screening enable antigen reactivity mapping in vitiligo. Immunity 2026. PubMed
- Knox JJ, O'Kane G, King D, Laheru D, Habowski AN, Yu K, Perez K, Aguirre AJ, Coyne Z, Harvey H, McLaughlin RA, Jang RW, Grant RC, Elimova EC, Renouf DJ, Fischer S, Duan K, Ramotar S, Jang GH, Zhang A, Devoe CE, Singh H, Pishvaian MJ, Froeling FEM, Saif MW, O'Reilly EM, Tsang ES, Wolpin BM, Wilson JM, Dodd A, Pugh TJ, Ye XY, Gallinger S, Tuveson DA, Notta F, Jaffee EM. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. J Clin Oncol 2025. PubMed
- Surana R, Morgado M, Somasundaram A, Bockorny B, Weekes CD, Coleman EC, Bird A, Wang J, Williams HL, Zheng H, Brais LK, Saxena N, Graham C, Ritterband L, Sawin M, Peters ML, Whooley P, Bullock A, Zerillo J, Sanoff HK, Clark JW, Parikh AR, Yurgelun MB, Patel AK, Mayer RJ, Cleary JM, Enzinger P, Rubinson DA, McCleary NJ, Enzinger A, Slater S, Ng K, Biller LH, Abrams TA, Huffman BM, Singh H, Raghavan S, Mancias JD, Bryant KL, Nowak JO, Aguirre AJ, Der CJ, Wolpin BM, Perez K. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer. JCO Precis Oncol 2025; 9:e2500332. PubMed
- El Khoury T, Magudia K, Schawkat K, Koch M, Cahill B, Clancy TE, Jajoo K, Mancias J, Singh H, Wolpin BM, Rosenthal MH. Biliary tract neoplasms from common to rare: diagnosis, assessment, and management. Abdom Radiol (NY) 2025. PubMed
- Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM. A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Clin Cancer Res 2025. PubMed
- Ardalan B, Ciner A, Baca Y, Hinton A, Darabi S, Kasi A, Lou E, Azqueta JI, Xiu J, Datta J, Shields AF, Aguirre A, Singh H, Shroff RT, Pishvaian MJ, Goel S. Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma. Clin Cancer Res 2025. PubMed
- Gaynor L, Singh H, Tie G, Badarinath K, Madha S, Mancini A, Bhattacharya S, Hoshino M, de Sauvage FJ, Murata K, Jadhav U, Shivdasani RA. Crypt density and recruited enhancers underlie intestinal tumour initiation. Nature 2025. PubMed
- Huffman BM, Rahma OE, Tyan K, Li YY, Giobbie-Hurder A, Schlechter BL, Bockorny B, Manos MP, Cherniack AD, Baginska J, Mariño-Enríquez A, Kao KZ, Maloney AK, Ferro A, Kelland S, Ng K, Singh H, Welsh EL, Pfaff KL, Giannakis M, Rodig SJ, Hodi FS, Cleary JM. A Phase 1 Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer. Cancer Immunol Res 2024. PubMed
- Singh H, Xiu J, Kapner KS, Yuan C, Narayan RR, Oberley M, Farrell A, Surana R, Huffman BM, Perez K, Cleary JM, Jordan AC, Dias Costa A, Williams HL, Raghavan S, Weinberg B, Pishvaian MJ, Shroff R, Goel S, Dougan SK, Nowak JA, Spetzler D, Sledge G, Wolpin BM, Aguirre AJ. Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer. Clin Cancer Res 2024. PubMed
- Singh H, Lowder KE, Kapner K, Kelly RJ, Zheng H, McCleary NJ, Abrams TA, Chan JA, Regan EM, Klempner SJ, Hannigan AM, Remland J, Brais LK, Andrews E, Yurgelun M, Cleary JM, Rubinson DA, Ritterhouse LL, Maron G, Aguirre AJ, Meyerhardt JA, Gardecki E, Lennerz JK, Wolpin BM, Enzinger PC. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma. Nat Commun 2024; 15:6833. PubMed
- Singh H, Li YY, Spurr LF, Shinagare AB, Abhyankar R, Reilly E, Brais LK, Nag A, Ducar MD, Thorner AR, Shapiro GI, Keller RB, Siletti C, Clark JW, Farago AF, Lin JJ, Demetri GD, Gujrathi R, Kulke MH, MacConaill LE, Ligon AH, Sicinska E, Meyerson M, Meyerhardt JA, Cherniack AD, Wolpin BM, Ng K, Giannakis M, Hornick JL, Cleary JM. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res 2021. PubMed
- Singh H, Liu Y, Xiao X, Lin L, Kim J, Van Hummelen P, Wu CL, Bass AJ, Saylor PJ. Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. 2016. PubMed
- Singh H, Longo DL, Chabner BA. Improving Prospects for Targeting RAS. J Clin Oncol 2015. PubMed
- Cheng XS, Adusumalli S, Singh H, DePasse JW, Smith RN, Haupert GT. The root of this evil: microangiopathic hemolytic anemia and renal failure. Am J Med 2015; 128:21-3. PubMed
- Singh H, Nikiforow S, Li S, Ballen KK, Spitzer TR, Soiffer R, Antin JH, Cutler C, Chen YB. Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol 2014. PubMed
- Singh H, Asali S, Werner LL, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Neuberg DS, Fox EA, Stone RM, Attar EC. Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res 2011. PubMed
- Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Schöll C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011; 146:697-708. PubMed
- Singh H, Werner LL, Asali S, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Wolpin B, Pidala J, Neuberg DS, Fox EA, Stone RM, Attar EC. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol 2011; 86:625-7. PubMed
- Singh H, Werner L, Deangelo D, Ballen K, Amrein P, Wadleigh M, Neuberg D, Fox E, Stone R, Attar E. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol 2010; 85:956-7. PubMed
- Chauhan S, Singh R, Singh H, Kaur R, Palleda GM. Sign of three. Am J Med 2009; 122:1013-5. PubMed
- Sharma BR, Harish D, Sharma A, Sharma S, Singh H. Injuries to neck structures in deaths due to constriction of neck, with a special reference to hanging. J Forensic Leg Med 2008; 15:298-305. PubMed
- Sharma BR, Gupta M, Sharma AK, Sharma S, Gupta N, Relhan N, Singh H. Suicides in Northern India: comparison of trends and review of literature. J Forensic Leg Med 2007; 14:318-26. PubMed